Theravance Biopharma/$TBPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Theravance Biopharma
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Ticker
$TBPH
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
97
ISIN
KYG8807B1068
Website
TBPH Metrics
BasicAdvanced
$531M
-
-$1.19
-0.10
-
Price and volume
Market cap
$531M
Beta
-0.1
52-week high
$11.82
52-week low
$7.44
Average daily volume
333K
Financial strength
Current ratio
4.77
Quick ratio
4.641
Long term debt to equity
22.502
Total debt to equity
29.013
Interest coverage (TTM)
-17.84%
Profitability
EBITDA (TTM)
-43.972
Gross margin (TTM)
38.52%
Net profit margin (TTM)
-89.38%
Operating margin (TTM)
-69.96%
Effective tax rate (TTM)
-20.65%
Revenue per employee (TTM)
$670,000
Management effectiveness
Return on assets (TTM)
-7.98%
Return on equity (TTM)
-31.46%
Valuation
Price to revenue (TTM)
8.006
Price to book
3.2
Price to tangible book (TTM)
3.2
Price to free cash flow (TTM)
16.185
Free cash flow yield (TTM)
6.18%
Free cash flow per share (TTM)
65.62%
Growth
Revenue change (TTM)
6.11%
Earnings per share change (TTM)
36.75%
3-year revenue growth (CAGR)
6.36%
10-year revenue growth (CAGR)
7.68%
3-year earnings per share growth (CAGR)
-16.32%
10-year earnings per share growth (CAGR)
-16.09%
What the Analysts think about TBPH
Analyst ratings (Buy, Hold, Sell) for Theravance Biopharma stock.
Bulls say / Bears say
Theravance Biopharma's key product, YUPELRI, achieved net sales of $58.3 million in Q1 2025, marking a 6% year-over-year increase, indicating strong market demand. (gurufocus.com)
TRELEGY, a product in collaboration with GSK, reported global net sales of $854 million in Q1 2025, a 14% rise compared to Q1 2024, showcasing robust growth in the respiratory market. (gurufocus.com)
BTIG analyst Julian Harrison increased the price target on Theravance Biopharma to $24.00, up from $21.00, citing strong TRELEGY sales and future royalty entitlements. (investing.com)
Theravance Biopharma reported a GAAP net loss of $13.6 million in Q1 2025, compared to $11.7 million in Q1 2024, with earnings per share of -$0.27 missing the forecast of -$0.22. (investing.com)
TD Cowen adjusted its outlook on Theravance Biopharma, lowering the price target to $9 from the previous $10, following the company's report of second-quarter financial results, which included a net loss of $17 million. (investing.com)
The completion of the CYPRESS study for ampreloxetine has been delayed, with the last patient enrollment now expected in mid-2025, postponing it from the second half of 2024. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
TBPH Financial Performance
Revenues and expenses
TBPH Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Theravance Biopharma stock?
Theravance Biopharma (TBPH) has a market cap of $531M as of June 20, 2025.
What is the P/E ratio for Theravance Biopharma stock?
The price to earnings (P/E) ratio for Theravance Biopharma (TBPH) stock is 0 as of June 20, 2025.
Does Theravance Biopharma stock pay dividends?
No, Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Theravance Biopharma dividend payment date?
Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Theravance Biopharma?
Theravance Biopharma (TBPH) has a beta rating of -0.1. This means that it has an inverse relation to market volatility.